Volume 8 Supplement 1

14th Scientific Symposium of the Austrian Pharmacological Society (APHAR)

Open Access

Chronic treatment with a selective neurokinin-1 receptor antagonist in a mouse model of trait anxiety and depression: focus on behaviour and neuropeptidergic mechanisms

  • Simone B Sartori1,
  • Stefano Gaburro1,
  • Rainer Landgraf2 and
  • Nicolas Singewald1Email author
BMC Pharmacology20088(Suppl 1):A19

https://doi.org/10.1186/1471-2210-8-S1-A19

Published: 5 November 2008

Current pharmacotherapy of anxiety disorders and depression mainly targets GABAA receptors and monoamines such as the serotonin and noradrenaline systems, respectively. They are effective, but an improvement of their therapeutic efficacy in regard of therapeutic onset, side effects and the number of treatment responders is desired. Here, we tested the sensitivity of a mouse line characterised by extremely high levels of trait anxiety and co-occurring depression (HAB) to the selective neurokinin-1 receptor (NK1R) antagonist [2-cyclopropoxy-5-(5-(trifluoromethyl)tetrazol-1-yl)benzyl]-(2-phenylpiperidin-3-yl)amine using a battery of established tests revealing anxiety- and depression-related behaviours. Chronic administration of the NK1R antagonist via the drinking water increased the time spent in the brightly lit compartment of the light/dark test and attenuated fear responses in a classical cued fear conditioning paradigm in male and female HAB animals. In addition, the enhanced immobility times of HABs displayed in the forced swim and tail suspension tests were reduced. These findings indicate a clear anxiolytic and antidepressant effect of chronic NK1R antagonist treatment in HAB animals which have not responded to any classical, clinically effective pharmacotherapy tested so far including paroxetine or diazepam. Moreover, they raise the possibility of a hyperactive substance P/NK1R neurotransmission in the HAB line. To test this hypothesis, we performed in situ hybridisation studies in the forebrain of HAB mice, their low anxiety/depression (LAB) counterparts and unselected CD1 (NAB) mice. Indeed, the abundance of Tac1 mRNA, the precursor of substance P was elevated in the habenula and ventromedial hypothalamus of HAB compared to NAB and/or LAB mice suggesting that up-regulated transcriptional processes in the substance P system may contribute to the enhanced anxiety- and depression-related behaviours of HABs. Chronic NK1R antagonist treatment did not alter the high Tac1 mRNA expression of HAB mice. In addition, the HAB vs. the other two lines displayed reduced BDNF mRNA expression in the dentate gyrus and increased met-enkephaline mRNA expression in the hippocampal CA3 region which both were not altered following chronic NK1R antagonist treatment. Taken together, the present results indicate that the HAB mouse line may represent a unique, clinically relevant model to study drug targets and underlying neurochemistry with potential clinical benefit in treatment-resistant pathological anxiety and co-occurring depression.

Declarations

Acknowledgements

Supported by the FWF W1206-B05 (NS).

Authors’ Affiliations

(1)
Department of Pharmacology and Toxicology and Center for Molecular Biosciences Innsbruck, University of Innsbruck
(2)
Department of Behavioural Neuroendocrinology, Max Planck Institute of Psychiatry

Copyright

© Sartori et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement